Rare Warning Letter Cites Alphatec For Post-Market Study Non-Compliance
This article was originally published in The Gray Sheet
FDA warned spinal implant and surgical instrument developer Alphatec Spine that failing to meet mandatory post-market study requirements for three 510(k)-cleared spine devices makes the products misbranded under the law.
You may also be interested in...
Warning Letter: Exoskeleton Firm Dodged Communication With FDA Over Postmarket Study, Failed To Assemble Surveillance Plan
An FDA warning letter sent to Argo Medical Technologies, now named ReWalk Robotics, outlines the company's failure to conduct mandatory postmarket surveillance activities on its ReWalk bionic walking assistance system. The missive to Argo also lays out a timeline of events that describes how the agency chased after the company.
Januvia and Janumet are misbranded, FDA tells Merck in a warning letter noting that rodent safety studies for the sitagliptin diabetes drugs were 20 months behind schedule. The letter marks the first time FDA has used its FDAAA powers to take enforcement action against a pharma company for such a delay.
FDA is emphasizing the need for “early and ongoing” interaction between regulators and device companies targeted by the agency in Section 522 post-market surveillance orders in a draft guidance issued Aug. 16.